Dividend stock investing has long been a cornerstone for building wealth, offering investors a steady stream of passive income while providing a buffer against market volatility.

HistoSonics, a medical technology company backed by Johnson & Johnson , is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing pe...

The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potent...

President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, al...

If you are someone who thinks investments should generate regular income, it is important to watch out for dividend stocks.

The first a approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis, 1 , 2 , 3 , 4 , 5 guselkumab showed statistically higher rates of...

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. It beat the consensus estimates again by a wide margin, thanks to its leading positions in the oncol...

Every so often, Wall Street offers a reminder to investors that, despite popular belief, stocks don't rise in a straight line. Although the annualized return of stocks over the last century trumps ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

In 2011, following the difficulty caused by the Great Recession, S&P Global Ratings (formerly Standard & Poor's) downgraded the long-term credit outlook of the United States from its highest design...

While it was fun while it lasted, as we have discussed before, inevitably, after vicious sell-offs like the one we saw from the market peak in February, which pushed the S&P 500 and the Nasdaq quic...

Another quarter of consistent growth for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato bodes well for other psychedelics, analysts at Jefferies believe. They see consistent quarter...

J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.